This company is a Phase 3 ORPHAN bio focusing in on IIH.
They have 31 mill cash on hand which will fully fund them all the way. They are currently valued at 40 mill MC so essentially 9 mill EV which is ridiculous for a Phase 3 bio.
Putting in a bottoming pattern now with a reverse head and shoulders developing.
A break of 80 cents will be the trigger point, at...
The yellow line shows level, green lines are meant to hit the yellow, down a little and break through the yellow trendline. In this case, the green bubble circled the low red dip shows it's doing the opposite. Hence, that's the STOP OUT sign.
GTFO!!
Invex Therapeutics aims to re-purpose a diabetic drug for brain disorders such as idiopathic intracranial hypertension, traumatic brain injury and acute stroke.
It only just listed but seems to be headed the right way price wise. It is already up another 16% today with 99 buyers for 659,825 units vs 30 sellers for 233,020 units. Pity I didn't see it sooner....
Invex Therapeutics aims to re-purpose a diabetic drug for brain disorders such as idiopathic intracranial hypertension, traumatic brain injury and acute stroke. As the product is already in production and use there is an easy route to entry.
Sector: Healthcare
Industry: Pharmaceuticals
Supply is being soaked and the price has been slowly appreciating due to...
